ArticleBritish journal of cancer2010
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Article in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 66 citations in OpenAlex.
- Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Cost-Effectiveness of Blinatumomab Plus Chemotherapy vs Chemotherapy in Adults Newly Diagnosed with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia in Italy.ClinicoEconomics and outcomes research : CEOR · 2026Article
- International cost-effectiveness analysis of chemoradiotherapy plus pembrolizumab for locally advanced cervical cancer.Journal of gynecologic oncology · 2025Article
- Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy.PharmacoEconomics · 2025Article
- Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands.Frontiers in oncology · 2023Article
- Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma.Frontiers in public health · 2022Article
- Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma.Therapeutic advances in medical oncology · 2022Article
- Lutetium oxodotreotide (BMC cancer · 2021Article
- Cost-Utility of Acromegaly Pharmacological Treatments in a French Context.Frontiers in endocrinology · 2021Article
- Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis.ClinicoEconomics and outcomes research : CEOR · 2021Article
- Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy.ClinicoEconomics and outcomes research : CEOR · 2021Article
- Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck.American journal of cancer research · 2020Article
- Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors.Frontiers in pharmacology · 2020Article
- Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.British journal of clinical pharmacology · 2019Article
- Article
- Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.Journal for immunotherapy of cancer · 2018Article
- Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Article
- A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.ClinicoEconomics and outcomes research : CEOR · 2017Article
- Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.ClinicoEconomics and outcomes research : CEOR · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBevacizumab plus interferon-alpha2a (IFN) prolongs progression-free survival to >10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell carcinoma (RCC). The two regimens have different tolerability profiles; therefore, costs for managing adverse events may be an important factor in selecting therapy.
methodsCosts of managing adverse events affecting patients with metastatic RCC eligible for treatment with bevacizumab plus IFN or sunitinib were evaluated using a linear decision analytical model. Management costs were calculated from the published incidence of adverse events and health-care costs for treating adverse events in the United Kingdom, Germany, France and Italy.
resultsAdverse event management costs were higher for sunitinib than for bevacizumab plus IFN. The average cost per patient for the management of grade 3-4 adverse events was markedly lower with bevacizumab plus IFN compared with sunitinib in the United Kingdom (euro1475 vs euro804), Germany (euro1785 vs euro1367), France (euro2590 vs euro1618) and Italy (euro891 vs euro402). The main cost drivers were lymphopaenia, neutropaenia, thrombocytopaenia, leucopaenia and fatigue/asthaenia for sunitinib; and proteinuria, fatigue/asthaenia, bleeding, anaemia and gastrointestinal perforation for bevacizumab plus IFN.
conclusionThe costs of managing adverse events are lower for bevacizumab plus IFN than for sunitinib. The potential for cost savings should be considered when selecting treatments for RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.